Clinical responses with T lymphocytes targeting malignancy-associated κ light chains.

ABSTRACT:

Background

Treatment of B cell malignancies with adoptive transfer of T cells with a CD19-specific chimeric antigen receptor (CAR) shows remarkable clinical efficacy. However, long-term persistence of T cells targeting CD19, a pan-B cell marker, also depletes normal B cells and causes severe hypogammaglobulinemia. Here, we developed a strategy to target B cell malignancies more selectively by taking advantage of B cell light Ig chain restriction. We generated a CAR that is specific for the κ light chain (κ.CAR) and therefore recognizes κ-restricted cells and spares the normal B cells expressing the nontargeted λ light chain, thus potentially minimizing humoral immunity impairment.

Methods

We conducted a phase 1 clinical trial and treated 16 patients with relapsed or refracto

SUBMITTER: Ramos CA 

PROVIDER: S-EPMC4922690 | biostudies-literature | 2016 Jul

REPOSITORIES: biostudies-literature